Phenacemide

• Catalog No.: DB01121
• CAS Number: 63-98-9
• M. F.: C9H10N2O2
• M. W.: 178.1879

SYNONYMS

• IUPAC name: (2-phenylacetyl)urea
• IUPAC Traditional name: phenacemide
• Brand Name: Neophedan; Fenacemide; Fenacemid; Phenurone; Felurea; Acetylureum; Epheron; Epiclase; Fenacetil-Karbamide; Fenilep; Fenural; Neophenal; Phenacereum; Phenicarb; Phenutal; Carbanmide; Cetylureum; Comitiadone; Eferon; Efron; Fenacetamide; Fenised; Fenostenyl; Fenurea; Fenurone; Fenylacetylmocovina; Fenytan; Phacetur; Phenacalum; Phenacetur; Phenarone; Phenuron; Phenyrit; Phetylureum
• Synonyms: PA; Phenacetylcarbamide; Phenylacetylurea; Carbamide phenylacetate; Phenacetylurea; Phenylacetyluree

DATABASE IDS

• PubChem CID: 4753
• PubChem SID: 46508400
• CAS Number: 63-98-9

PROPERTIES

• Hydrophobicity(logP): 0.8
• Solubility: 10.2 g/L

DETAILS

Description (English)

• Drug Groups: approved
• Description: Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.
• Indication: Used to control certain seizures in the treatment of epilepsy.
• Pharmacology: Phenacemide is a ureal anticonvulsant indicated for control of severe epilepsy, particularly mixed forms of complex partial (psychomotor or temporal lobe) seizures, refractory to other anticonvulsants. Phenacemide elevates the threshold for minimal electroshock convulsions and abolishes the tonic phase of maximal electroshock seizures. It also prevents or modifies seizures induced by pentylenetetrazol or other convulsants.
• Toxicity: Oral, mouse: LD₅₀ = 987 mg/kg; Oral, rabbit: LD₅₀ = 2500 mg/kg; Oral, rat: LD₅₀ = 1600 mg/kg
• Affected Organisms: Humans and other mammals
• Biotransformation: Metabolized in the liver by hepatic microsomal enzymes, where it is inactivated by p-hydroxylation.
• Absorption: Almost completely absorbed.
• Half Life: 22-25 hours.
• References: Coker SB: The use of phenacemide for intractable partial complex epilepsy in children. Pediatr Neurol. 1986 Jul-Aug;2(4):230-2. [Pubmed] ; Coker SB, Holmes EW, Egel RT: Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6. [Pubmed]
• External Links: Wikipedia

REFERENCES

• Coker SB: The use of phenacemide for intractable partial complex epilepsy in children. Pediatr Neurol. 1986 Jul-Aug;2(4):230-2. Pubmed
• Coker SB, Holmes EW, Egel RT: Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6. Pubmed